Has

Indications for use

The use of Imet is indicated for the symptomatic treatment of pain of mild to moderate intensity:

Diseases of the musculoskeletal system: osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and other inflammatory and degenerative pathologies; psoriatic arthritis, articular syndrome with exacerbation of gout;
Bursitis, tendovaginitis;
Post-traumatic pain in joints and muscles;
Toothache and headache;
Acute respiratory viral infections (as part of complex therapy);
Algodismenorrhea, adnexitis;
Feverish conditions of various origins.

Contraindications

Severe renal and/or liver dysfunction;
Severe form of cardiovascular failure;
Peptic ulcers, hemorrhage, including a history;
Functional disorders of the hematopoietic system associated with a tendency to active bleeding, including gastrointestinal and cerebrovascular bleeding;
Aspirin triad (history);
Concomitant use of selective cyclooxygenase-2 inhibitors or other non-steroidal anti-inflammatory drugs;
Age up to 12 years;
III trimester of pregnancy;
Hypersensitivity to the components of the drug and other non-steroidal anti-inflammatory drugs.

It is recommended to prescribe Imet with caution to: elderly patients due to the increased risk of bleeding, including death; with systemic lupus erythematosus, arterial hypertension, mixed collagenosis, cardiovascular failure, impaired renal and liver function; in the first and second trimesters of pregnancy, during breastfeeding; immediately after surgery.

Name: Imet Pharmacological action: Imet is a drug from the group of non-steroidal anti-inflammatory drugs. Imet contains the active substance - ibuprofen - a derivative of phenylpropionic acid, consisting of a racemic mixture of R- and S-enantiomers. It has anti-inflammatory, analgesic and antipyretic activity. Helps eliminate pain during dysmenorrhea, joint diseases and in the postoperative period. Ibuprofen relieves headaches, dental and muscle pain. In patients with inflammatory diseases of the musculoskeletal system, the drug reduces morning stiffness and swelling of joints, increases range of motion, eliminates or weakens pain. The mechanism of action of the drug is based on its ability to disrupt the metabolism of arachidonic acid by inhibiting the enzyme cyclooxygenase. Ibuprofen is a non-selective non-steroidal anti-inflammatory drug and equally inhibits both isoforms of cyclooxygenase - cyclooxygenase-1 and cyclooxygenase-2. Due to impaired metabolism of arachidonic acid, the production of pro-inflammatory prostaglandins E and F, prostacyclins and thromboxane is reduced. By reducing the amount of prostaglandins at the site of inflammation, the synthesis of bradykinin, endogenous pyrogens and other biologically active substances decreases, which leads to a decrease in the activity of the inflammatory process and a decrease in irritation of pain receptors. Ibuprofen, by reducing the amount of prostaglandins directly in the thermoregulation center in the hypothalamus, helps lower body temperature and eliminate fever.

By reducing the production of thromboxane from arachidonic acid, ibuprofen, like other nonsteroidal anti-inflammatory drugs, has some antiplatelet effect. A number of studies have established the effect of ibuprofen on the synthesis of endogenous interferon. When using the drug Imet, irritation of the gastric mucosa is observed in patients much less frequently than when using salicylates.

After oral administration of the drug Imet, the active substance is well absorbed from the gastrointestinal tract. Ibuprofen is absorbed primarily in the small intestine, however, some of the drug is absorbed in the stomach. The peak concentration of the active substance in the blood plasma is observed 1-2 hours after oral administration; ibuprofen is characterized by a high degree of association with plasma lobes (up to 99%). When taking the drug simultaneously with food, the time to reach maximum plasma concentration increases by an average of 30-60 minutes, however, the bioavailability of the drug does not change. The drug is metabolized in the liver by hydroxylation and carboxylation; as a result of metabolism, pharmacologically inactive metabolites are formed. The drug does not accumulate in the body, however, penetrating into the synovial fluid, it maintains a therapeutic concentration in it for a long time. It is excreted primarily by the kidneys in the form of pharmacologically inactive metabolites; a small part of the drug is excreted by the liver in the form of pharmacologically inactive metabolites and unchanged ibuprofen. The half-life is about 2-2.5 hours, and is completely eliminated from the body within 24 hours. Pharmacokinetics in patients with impaired liver and/or renal function corresponds to the pharmacokinetics of ibuprofen in healthy volunteers.

Indications for use: The drug is used for various inflammatory diseases that are accompanied by pain, including the drug is used to treat patients with the following diseases: Inflammatory-degenerative diseases of the musculoskeletal system, which are accompanied by pain of mild to moderate intensity: rheumatoid arthritis, osteoarthritis , ankylosing spondylitis. Pain syndrome of weak and moderate intensity in diseases of the musculoskeletal system of another etiology: articular syndrome during exacerbation of gout, psoriatic arthritis. Pain syndrome in inflammatory diseases of soft tissues: tenosynovitis, bursitis. Post-traumatic pain in muscles and joints. In addition, the drug is used to treat patients with pain of mild to moderate intensity of unknown etiology: toothache and headache, adnexitis, algodismenorrhea. Imet is used to reduce elevated body temperature, which is accompanied by inflammatory diseases of infectious etiology. The drug can be prescribed in combination with other drugs for the treatment of inflammatory diseases of the ENT organs of infectious etiology, which are accompanied by pain of mild or moderate intensity and/or fever. Imet can be prescribed to reduce elevated body temperature in the period after vaccination.

Directions for use: The drug is taken orally, it is recommended to swallow the tablet whole, without chewing or crushing, with a sufficient amount of water. If necessary, the tablet can be divided. To reduce the severity and reduce the risk of side effects, it is recommended to take the drug during or after meals. The dosage of the drug and the duration of treatment are determined by the attending physician individually for each patient, depending on the nature of the disease and the patient’s personal characteristics. Children over 12 years of age with pain of mild to moderate intensity are usually prescribed 200-400 mg of the drug (1/2-1 tablet of the drug Imet) 2-3 times a day. It is recommended to maintain an interval between doses of the drug of at least 4 hours. The maximum daily dose of the drug is 1000 mg (2.5 tablets of the drug Imet). To reduce elevated body temperature, children over 12 years of age are usually prescribed 200-400 mg of the drug (1/2-1 tablet of the drug Imet) once; if necessary, the drug can be repeated after 4 hours. The maximum daily dose of the drug is 1000 mg (2.5 tablets of the drug Imet).

Adults and adolescents over the age of 15 years with pain of mild to moderate intensity are usually prescribed 200-400 mg of the drug (1/2-1 tablet of the drug Imet) 2-3 times a day. It is recommended to maintain an interval between doses of the drug of at least 4 hours. The maximum daily dose of the drug is 1200 mg (3 tablets of the drug Imet). To reduce elevated body temperature, adults and adolescents over 15 years of age are usually prescribed 200-400 mg of the drug (1/2-1 tablet of the drug Imet) once. If necessary, the drug can be repeated after 4 hours. The maximum daily dose of the drug is 1200 mg (3 tablets of the drug Imet). Elderly patients do not require dose adjustment of the drug.

Side effects: When using the drug, patients experienced the development of the following side effects: From the cardiovascular system: arrhythmia, heart failure, arterial hypertension. In isolated cases, when using high doses of the drug, myocardial infarction may develop. From the hematopoietic system: anemia, thrombocytopenia, pancytopenia, leukopenia, agranulocytosis. If the function of the hematopoietic system is impaired, patients experience the development of a sore throat, erosive lesions of the oral mucosa, increased body temperature, muscle pain, and depression. In addition, bleeding of unknown etiology may develop, including skin hemorrhages, hematomas and nosebleeds. If long-term use of the drug Imet is necessary, it is recommended to regularly monitor the hemogram. From the central and peripheral nervous system: headache, dizziness, disturbance of sleep and wakefulness, increased fatigue, irritability. In addition, the development of psychotic reactions, depression, emotional lability and feelings of causeless anxiety is possible. In isolated cases, the development of psychomotor agitation and seizures was noted. From the senses: with long-term use of the drug Imet, visual impairment is possible, including decreased clarity of vision, dryness of the mucous membrane of the eye and impaired color perception. It is also possible to develop tinnitus and hearing impairment.

From the gastrointestinal tract: pain in the epigastric region, nausea, vomiting, heartburn, indigestion, dry mouth, flatulence, stool disorders (possible development of both diarrhea and constipation). In some cases, it is possible to develop gastrointestinal bleeding, ulcerative lesions of the stomach and duodenum (including ulcerative lesions that are accompanied by perforation and bleeding), and ulcerative stomatitis. In addition, some patients experienced exacerbation of colitis and Crohn's disease, as well as the development of gastritis, esophagitis and pancreatitis. In isolated cases, the development of duodenitis was observed during therapy with the drug Imet. In case of gastrointestinal bleeding (patients experience vomiting the color of coffee grounds, black stools and severe pain in the epigastric region), the drug should be stopped and contacted by your doctor. From the liver: toxic liver damage, acute liver failure, liver dysfunction, hepatorenal syndrome, hepatitis. From the genitourinary system: edema (occurring mainly in patients suffering from arterial hypertension and/or renal failure), interstitial nephritis, nephrotic syndrome, necrosis of the renal papillae, hyperuricemia, polyuria, oliguria, cystitis. In isolated cases, the development of hematuria and glomerulonephritis was noted. If long-term use of the drug Imet is necessary, it is recommended to monitor renal function.

From the skin: Stevens-Johnson syndrome, Lyell's syndrome, photosensitivity, dry skin, alopecia. Infectious and parasitic diseases: in isolated cases, when using the drug Imet, patients experienced the development or exacerbation of infectious diseases, such as necrotizing fasciitis, which can be caused by taking non-steroidal anti-inflammatory drugs. In the event of a new infection or exacerbation of an existing infectious disease, it is recommended to consult your doctor, who may stop taking ibuprofen and prescribe antibacterial therapy. In isolated cases, when using the drug Imet, patients experienced the development of symptoms of aseptic meningitis, including hyperthermia, headache, stiff neck, nausea, vomiting and impaired consciousness. The development of symptoms of aseptic meningitis was more often observed in patients suffering from autoimmune diseases, including systemic lupus erythematosus and mixed collagenosis. Allergic reactions: skin rash, itching, rhinitis, urticaria, erythema multiforme, anaphylactoid reactions, including swelling of the tongue and larynx, arterial hypotension, up to anaphylactic shock. In patients with increased individual sensitivity, bronchospasm and attacks of bronchial asthma may develop. If allergic reactions develop, you must stop taking the drug and consult a doctor as soon as possible, since in some cases the patient may need emergency medical care. Others: with long-term use of the drug in high doses, there is an increased risk of arterial thromboembolism and stroke.

Contraindications: Increased individual sensitivity to the components of the drug and other drugs from the group of non-steroidal anti-inflammatory drugs. History of aspirin triad (aspirin triad includes the development of bronchospasm and allergic rhinitis after the use of acetylsalicylic acid, as well as aspirin intolerance). The drug is not prescribed to patients who are taking other drugs from the group of non-steroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors. Disturbances in the function of the hematopoietic system of unknown etiology, a tendency to gastrointestinal bleeding, the presence of active bleeding, including cerebrovascular bleeding. Peptic ulcers or hemorrhages, including a history. The drug is contraindicated in patients suffering from severe liver and/or kidney dysfunction, as well as severe heart failure.

The drug is not prescribed to women in the third trimester of pregnancy, or to children under 12 years of age. The drug is recommended to be prescribed with caution to elderly patients, as they have an increased risk of bleeding, including death. Therapy for elderly patients is recommended to begin with a minimum single dose and, if necessary, gradually increase the dose of the drug until the required therapeutic effect is achieved. The drug is prescribed with caution to patients suffering from systemic lupus erythematosus, mixed collagenosis, arterial hypertension, heart failure, impaired liver and kidney function. The drug is prescribed with caution immediately after surgery. The drug is used with caution in women in the first and second trimesters of pregnancy and during lactation. It is not recommended to prescribe the drug to patients whose work involves operating potentially dangerous machinery or driving a car.

Pregnancy: The drug can be prescribed by the attending physician in the first and second trimester of pregnancy for health reasons. When prescribing the drug Imet, the attending physician must carefully weigh the expected benefits for the mother and the potential risks for the fetus. The use of the drug Imet is contraindicated in the third trimester of pregnancy, since ibuprofen can cause premature closure of the ductus arteriosus in the fetus. It is also possible to delay the onset of labor, increase the duration of the labor period and increase the risk of bleeding in mother and child. The drug is excreted in small amounts into breast milk, however, no negative effects were observed in newborns whose mothers received ibuprofen therapy.

Interaction with other drugs: When used simultaneously, the drug reduces the antihypertensive effect of ACE inhibitors and beta-blockers. When used simultaneously, it reduces the pharmacological effect of furosemide, hypothiazide and other diuretics. Ibuprofen enhances the effect of anticoagulants; with the simultaneous use of these drugs, the risk of developing gastrointestinal bleeding increases. When using the drug simultaneously with glucocorticosteroids, the risk of developing side effects from the digestive tract increases. Ibuprofen, when used simultaneously, displaces indirect anticoagulants, oral hypoglycemic drugs, sulfonylurea derivatives and hydantoin derivatives from binding to plasma proteins. When used simultaneously, the drug slightly reduces the antihypertensive effect of amlodipine, hydrochlorothiazide and captopril.

When used simultaneously, ibuprofen increases the toxic effect of baclofen and methotrexate. Acetylsalicylic acid helps reduce the plasma concentration of ibuprofen. With the simultaneous use of the drug Imet with warfarin, an increase in bleeding time and the development of microhematuria and hematomas are observed. Cholestyramine, when used simultaneously, reduces the absorption of ibuprofen in the gastrointestinal tract. The drug, when used simultaneously with lithium preparations, helps to increase plasma concentrations of lithium; in addition, the drug helps to increase plasma concentrations of phenytoin and digoxin when used simultaneously. Magnesium hydroxide, when used simultaneously with the drug Imet, increases the initial absorption of ibuprofen in the gastrointestinal tract.

Overdose: When using excessive doses of the drug, patients experience the development of disorders of the central nervous system, including headache, decreased speed of psychomotor reactions, drowsiness, ringing in the ears, dizziness; in children, the development of myoclonic convulsions is possible. In addition, in case of an overdose of the drug, patients experience nausea, vomiting, pain in the epigastric region, vomit the color of coffee grounds (which indicates the development of gastrointestinal bleeding), impaired renal and/or liver function, and attacks of bronchial asthma. With a further increase in dose, patients develop depression of respiratory function, cyanosis, nystagmus, arterial hypotension, fainting, acute renal failure, metabolic acidosis, coma. There is no specific antidote. In case of an overdose of the drug, gastric lavage, intake of enterosorbents and symptomatic therapy are indicated. In case of respiratory arrest, immediate resuscitation measures are indicated.

Release form: Film-coated tablets, 10 pieces in a blister, 1, 2 or 3 blisters in a cardboard package.

Storage conditions: It is recommended to store the drug in a dry place away from direct sunlight at a temperature of 15 to 30 degrees Celsius. Shelf life – 3 years.

Synonyms: Ibuprom, Ibuprofen, Nurofen.

Composition: 1 film-coated tablet contains: Ibuprofen – 400 mg; Excipients.

Attention! The description of the drug “ Imet ” on this page is a simplified and expanded version of the official instructions for use. Before purchasing or using the drug, you should consult your doctor and read the instructions approved by the manufacturer. Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.

Directions for use and dosage

The tablets are taken orally, without chewing, during or immediately after meals, with a sufficient amount of water.

The dose and duration of use are prescribed by the doctor individually, taking into account the clinical indications and the patient’s condition.

Recommended daily dosage:

Pain syndrome of weak and moderate intensity: 200-400 mg 2-3 times a day with an interval between doses of at least 4 hours;
Feverish conditions of various origins: 200-400 mg 1 time per day, if necessary, repeated administration is allowed after 4 hours.

The maximum daily dose for patients over 15 years of age is 1200 mg, for children over 12 years of age – 1000 mg.

For elderly patients, no dose adjustment is required.

Side effects

From the gastrointestinal tract: nausea, epigastric pain, vomiting, dry mouth, heartburn, flatulence, indigestion, diarrhea or constipation; possible - ulcerative lesions of the stomach and duodenum (including with perforation and bleeding), gastrointestinal bleeding, ulcerative stomatitis, exacerbation of colitis and Crohn's disease, esophagitis, gastritis, pancreatitis; in isolated cases – duodenitis;
From the cardiovascular system: heart failure, arrhythmia, arterial hypertension; possible – development of myocardial infarction (when taking high doses);
From the nervous system: dizziness, headache, sleep disturbances, irritability, increased fatigue; possibly depression, emotional lability, feelings of causeless anxiety and other psychotic reactions; in isolated cases – convulsions, psychomotor agitation;
From the hematopoietic system: thrombocytopenia, anemia, pancytopenia, agranulocytosis, leukopenia; in patients with impaired function of the hematopoietic system - erosive lesions of the oral mucosa, sore throat and/or muscle pain, increased body temperature, depression; possible - hematomas, skin hemorrhages, nosebleeds and other bleeding of unknown etiology;
From the hepatobiliary system: functional liver disorders, toxic liver damage, hepatitis, acute liver failure, hepatorenal syndrome;
From the senses: blurred vision (with long-term use), including dryness of the mucous membrane and color perception of the eye, decreased clarity of vision; possible – hearing impairment, tinnitus;
From the genitourinary system: edema (mainly in patients with arterial hypertension and/or renal failure), necrosis of the renal papillae, interstitial nephritis, hyperuricemia, nephrotic syndrome, polyuria, cystitis, oliguria; in isolated cases - hematuria, glomerulonephritis;
Allergic reactions: itching, skin rash, rhinitis, erythema multiforme, urticaria, anaphylactoid reactions, including swelling of the tongue and larynx, arterial hypotension, anaphylactic shock; possible – development of bronchospasm and bronchial asthma in patients with increased individual sensitivity;
From the skin: dry skin, Stevens-Johnson syndrome, alopecia, Lyell's syndrome, photosensitivity;
Other: arterial thromboembolism, stroke (with long-term use in high doses).

In addition, undesirable effects of using Imet can be an exacerbation or development of infectious diseases: necrotizing fasciitis, aseptic meningitis (symptoms - stiff neck, hyperthermia, nausea, headache, vomiting, impaired consciousness).

Side effects

Like all non-steroidal drugs, Imet can have a negative effect on various systems of the human body, which manifest themselves in the form of:

Abdominal pain, constipation, diarrhea, heartburn, nausea, bloating, stomach and intestinal ulcers;
Headaches;
Edema, decreased diuresis, damage to liver tissue, necrosis of the renal papillae;
Hematopoietic disorders;
Severe allergic reactions, in particular rash with blisters and redness, asthma attacks;
Decreased blood pressure, shortness of breath, edema and tachycardia.

special instructions

Elderly patients should be prescribed a minimum single dose at the beginning of treatment; if necessary and normal tolerability of the drug, it can be gradually increased.

If allergic reactions develop, the patient should stop taking it and immediately consult a doctor for advice.

With long-term use of Imet, regular monitoring of hemograms and renal function is recommended.

If gastrointestinal bleeding develops, the signs of which are severe pain in the epigastric region, vomit the color of coffee grounds, black stools, you must stop taking the drug and consult a doctor.

If an infectious pathology worsens or a new infection develops while using ibuprofen, the patient should consult a doctor to prescribe antibacterial therapy.

During the period of use of Imeta, patients are advised to refrain from performing potentially hazardous types of work, including driving vehicles and machinery.

Drug interactions Imet

Ibuprofen, like other NSAIDs, should be taken with caution in combination with drugs such as acetylsalicylic acid or other NSAIDs and corticosteroids (increased risk of stomach and intestinal ulcers, gastrointestinal bleeding), excluding their local use; antihypertensive drugs and diuretics (ibuprofen may weaken their effect); with agents that inhibit blood clotting (control of the blood coagulation system); with lithium (control of lithium levels in the blood); methotrexate (increased side effects); cidovudine (increased risk of hemarthrosis and hematomas in HIV-infected patients).

Drug interactions

When taken simultaneously, Imet reduces the antihypertensive effect of amlodipine, captopril, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers; pharmacological effect of furosemide, hypothiazide, hydrochlorothiazide and other diuretics.

The drug enhances the effect of anticoagulants, increasing the risk of gastrointestinal bleeding.

Ibuprofen in combination with lithium preparations, phenytoin, digoxin helps to increase the level of their concentration in the blood plasma.

When taken simultaneously, the drug displaces indirect anticoagulants, sulfonylurea derivatives, oral hypoglycemic agents and hydantoin derivatives from their bonds with blood plasma proteins; increases the toxic effect of methotrexate and baclofen.

With simultaneous use of Imeta:

Cholestyramine – helps reduce the absorption of ibuprofen in the gastrointestinal tract;
Warfarin – promotes the development of microhematuria and hematomas, increasing the period of bleeding;
Acetylsalicylic acid - reduces the plasma concentration of ibuprofen;
Magnesium hydroxide – increases the initial absorption of ibuprofen in the gastrointestinal tract;
Glucocorticosteroids - increase the likelihood of developing side effects from the digestive system.

Pharmacological properties of the drug Imet

Ibuprofen is an NSAID whose action is associated with inhibition of prostaglandin synthesis. It reduces pain, swelling and fever caused by inflammation. In addition, ibuprofen inhibits platelet aggregation caused by ADP and collagen. When administered orally, ibuprofen is partially absorbed in the stomach and completely absorbed in the small intestine. Undergoing biotransformation in the liver (hydroxylation, carboxylation), pharmacologically inactive metabolites are completely excreted, mainly by the kidneys (90%), and are also excreted through the hepatobiliary system. The half-life in healthy people and in patients with liver and/or kidney diseases is 1.8–3.5 hours. Plasma protein binding after oral administration is 99%. Peak serum concentrations after oral administration are achieved within 1–2 hours.